LISINOPRIL tablet

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL - UNII:E7199S1YWR)

可用日期:

McKesson Contract Packaging

INN（国际名称）:

LISINOPRIL

组成:

LISINOPRIL 2.5 mg

处方类型:

PRESCRIPTION DRUG

授权状态:

Abbreviated New Drug Application

产品特点

LISINOPRIL- LISINOPRIL TABLET
MCKESSON CONTRACT PACKAGING
----------
LISINOPRIL TABLETS USP
USE IN PREGNANCY
WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, ACE
INHIBITORS CAN CAUSE
INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is
detected, lisinopril should be
discontinued as soon as possible. See WARNINGS: Fetal/Neonatal
Morbidity and Mortality.
DESCRIPTION
Lisinopril is an oral long-acting angiotensin converting enzyme
inhibitor. Lisinopril, a synthetic peptide
derivative, is chemically described as (S)-1-[_N_
-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline
dihydrate. Its molecular formula is C
H N O 2H O and its structural formula is:
Lisinopril, USP is a white to off-white, crystalline powder, with a
molecular weight of 441.53. It is
soluble in water and sparingly soluble in methanol and practically
insoluble in ethanol.
Lisinopril is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg or 40 mg
tablets for oral administration.
Inactive ingredients:
2.5 mg, 5 mg, 10 mg tablets - dibasic calcium phosphate dihydrate,
povidone, pregelatinized starch,
mannitol, colloidal silicon dioxide, corn starch, magnesium stearate.
20 mg, 30 mg, 40 mg tablets - dibasic calcium phosphate dihydrate,
povidone, pregelatinized starch,
mannitol, colloidal silicon dioxide, corn starch, magnesium stearate,
ferric oxide yellow (for 20 mg),
ferric oxide red (for 30 mg) and ferric oxide brown (for 40 mg).
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Lisinopril inhibits angiotensin converting enzyme (ACE) in human
subjects and animals. ACE is a
peptidyl dipeptidase that catalyzes the conversion of angiotensin I to
the vasoconstrictor substance,
angiotensin II. Angiotensin II also stimulates aldosterone secretion
by the adrenal cortex. The beneficial
effects of lisinopril in hypertension and heart failure appear to
result primarily from suppression of the
renin-angiotensin-aldosterone system. Inhibition of ACE results in
decreased plasma angiotensin II
which leads to decreased vasopressor activity and to decreased
al